作者: Volker Kunzmann , Thomas Ruediger , Michael Hallek , Hans-Konrad Mueller-Hermelink , Martin Wilhelm
关键词:
摘要: The chimeric monoclonal anti-CD20 antibody has been widely used for the treatment of relapsed or refractory low-grade B-cell non-Hodgkin lymphoma (NHL). However, in patients with a high number tumor cells blood, severe infusion-related toxicities have reported.[1][1] On basis